Cargando…
mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach
The U.S. Food and Drug Administration (FDA) has recently issued an Emergency Use Authorization (EUA) for 2 highly effective coronavirus disease 2019 (COVID-19) vaccines from Pfizer-BioNTech and Moderna. This has brought hope to millions of Americans in the midst of an ongoing global pandemic. The FD...
Autores principales: | Banerji, Aleena, Wickner, Paige G., Saff, Rebecca, Stone, Cosby A., Robinson, Lacey B., Long, Aidan A., Wolfson, Anna R., Williams, Paul, Khan, David A., Phillips, Elizabeth, Blumenthal, Kimberly G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948517/ https://www.ncbi.nlm.nih.gov/pubmed/33388478 http://dx.doi.org/10.1016/j.jaip.2020.12.047 |
Ejemplares similares
-
COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach
por: Banerji, Aleena, et al.
Publicado: (2021) -
First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing
por: Wolfson, Anna R., et al.
Publicado: (2021) -
Reply to “PEG skin testing for COVID-19 allergy”
por: Banerji, Aleena, et al.
Publicado: (2021) -
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
por: Blumenthal, Kimberly G., et al.
Publicado: (2021) -
The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis
por: Shaker, Marcus, et al.
Publicado: (2021)